Emily M. Leproust Sells 1,726 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,726 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the sale, the chief executive officer now owns 660,966 shares of the company’s stock, valued at $27,549,062.88. The trade was a 0.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Twist Bioscience Price Performance

TWST stock traded up $2.05 during trading on Monday, reaching $44.94. 724,963 shares of the company were exchanged, compared to its average volume of 924,609. The company has a market cap of $2.68 billion, a P/E ratio of -13.30 and a beta of 2.15. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The stock’s 50 day moving average price is $45.40 and its 200 day moving average price is $45.27. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business’s revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.75) earnings per share. As a group, analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in shares of Twist Bioscience in the 3rd quarter valued at $714,000. Massachusetts Financial Services Co. MA lifted its position in Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after acquiring an additional 20,035 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Twist Bioscience by 4.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 524,942 shares of the company’s stock worth $23,717,000 after acquiring an additional 24,582 shares during the period. Algert Global LLC grew its position in Twist Bioscience by 59.7% in the third quarter. Algert Global LLC now owns 43,592 shares of the company’s stock valued at $1,969,000 after acquiring an additional 16,292 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Twist Bioscience during the third quarter valued at approximately $599,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on TWST shares. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird upped their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Finally, Wolfe Research initiated coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.